Still Looking For The Off-The-Shelf Breakthrough, Allogene Touts Myeloma CAR-T Candidate

Raises Hopes Of Challenging Abecma And Carvykti

While a cloud hangs over the future of its CD19-targeting allogeneic candidate, Allogene points to preclinical potential of superior efficacy for ALLO-715.

Allogene building
Allogene's CD19-targeting off-the-shelf CAR-Ts have hit setbacks, putting pressure on its multiple myeloma targeting candidates to succeed. • Source: Alamy

Allogene Therapeutics has repeatedly stumbled in its efforts to develop the first off-the-shelf CAR-T therapy for B-cell lymphoma, but is now touting preclinical data suggesting its platform could produce a more effective product than already-marketed autologous multiple myeloma CAR-Ts.

That is significant as its lead candidate, ALLO-501A, has yet to demonstrate durable efficacy to match the established autologous CAR-Ts...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Anticancer

More from Therapeutic Category